News|Articles|April 2, 2026

Why Does the Future of Genetic Medicines Rely on LNP Targeting Strategies? Read What Experts Have to Say

Experts from Acuitas, Mana.bio, NanoVation, and ReCode share their input on targeted LNP engineering, which is accelerating pipeline expansion of nucleic acid therapies for chronic and rare diseases beyond the liver.

The success of lipid nanoparticle (LNP)-based vaccines has established LNPs as the foundational delivery vehicle for nucleic acid therapeutics. Today, the major effort being seen in the nanomedicine space is the targeting of specific tissues/organs. This shift is essential for expanding genetic medicines beyond vaccine applications and into chronic diseases, tumors, and rare metabolic disorders.^1,2